Brief: Acorda Therapeutics Reports First Quarter 2021 Financial Results
06/05/2021 21:02
May 6 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL
RESULTS
* Q1 NON-GAAP LOSS PER SHARE $2.46
* Q1 GAAP LOSS PER SHARE $3.53
* ACORDA THERAPEUTICS - FOR FULL-YEAR 2021, CONTINUES TO
EXPECT
AMPYRA NET REVENUE TO BE $75 - $85 MILLION, AND OPERATING
EXPENSES TO BE $130 - $140 MILLION
* QTRLY TOTAL REVENUES $28.9 MILLION VERSUS $28.1 MILLION
Source text for Eikon: ID:nBw1cRFvna
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease